Affimed N.V. (NASDAQ:AFMD)
Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany.
Affimed N.V. (NASDAQ:AFMD)’s Financial Overview
Affimed N.V. (NASDAQ) surged 3.01% yesterday to close its trading session at $3.42. The company has 1 year Price Target of $7.86. Affimed N.V. has 52-Week high of $7.35 and 52-Week Low of $1.4. The stock touched its 52-Week High on 7.35 and 52-Week Low on 1.40. The stock traded with the volume of 247994 shares yesterday. The firm shows the market capitalization of $218.2 Million.
Affimed N.V. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.22/share against the analyst consensus estimate of $-0.17/share. The difference between the actual and expected EPS is $-0.05 a share with a surprise factor of -29.4%.
The firm is trading with SMA20 of 0.4 Percent, SMA50 of -2.53 Percent and SMA200 of 13.33 percent. Affimed N.V. has P/S value of 121.22 while its P/B value stands at 5.34. Similarly, the company has Return on Assets of -63.5 percent, Return on Equity of -82.1 percent and Return on Investment of -70.4 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 5 analysts offering 12-month price forecasts for Affimed NV have a median target of 6.00, with a high estimate of 15.00 and a low estimate of 6.00. The median estimate represents a +75.44% increase from the last price of 3.42.
Affimed N.V. is estimated to report earnings on 03/19/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.17. The reported EPS for the same quarter last year was $-0.16.
Expeditors International of Washington, Inc. (NASDAQ:EXPD)
Expeditors International of Washington, Inc. is a leading provider of global logistics solutions. A Fortune 500 service-based logistics company provides, it offers its customers a seamless international network supporting the movement and strategic positioning of goods. The company’s services include the consolidation or forwarding of air and ocean freight. And customized logistics solutions. In each U.S. office, and in many overseas offices, the company acts as a customs broker. The company also provides additional services including distribution management, vendor consolidation, cargo insurance, and purchase order management. Expeditors International generates highly optimized and customized supply chain solutions for their clients with unified technology systems integrated through a global network of 331 locations in 109 countries on six continents. The company also provides additional services including distribution management, vendor consolidation, cargo insurance, and purchase order management.
Expeditors International of Washington, Inc. (NASDAQ:EXPD)’s Financial Outlook
The 12 analysts offering 12-month price forecasts for Expeditors International of Washington Inc have a median target of 70.50, with a high estimate of 78.00 and a low estimate of 57.00. The median estimate represents a -0.94% decrease from the last price of 71.17.
Expeditors International of Washington, Inc. is expected* to report earnings on 02/19/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.85. The reported EPS for the same quarter last year was $0.71.
According to Zacks Investment Research, Expeditors International of Washington, Inc. has a Consensus Recommendation of 3. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 0.07% and closed its last trading session at $71.17. The company has the market capitalization of $12.33 Billion. The stock has 52-week high of $78.16 and 52-Week low of $60.7. The firm touched its 52-Week high on 78.16 and 52-Week low on 59.10. The company has volume of 876903 shares. The company has a total of 173.27 Million shares outstanding.
Expeditors International of Washington, Inc. (NASDAQ) in the last quarter reported its actual EPS of $0.92/share where the analyst estimated EPS was $0.79/share. The difference between the actual and Estimated EPS is $0.13. This shows a surprise factor of 16.5 percent.
The company has YTD performance of 4.52 percent. Beta for Expeditors International of Washington, Inc. stands at 0.78 while its ATR (average true range) is 1.25. The company has Weekly Volatility of 1.08%% and Monthly Volatility of 1.79%%.
Expeditors International of Washington, Inc. has distance from 20-day Simple Moving Average (SMA20) of 2.97%, Distance from 50-Day Simple Moving Average of 2.31 percent and Distance from 200-Day Simple Moving Average of -0.63%.
The Company currently has ROA (Return on Assets) of 18.9 percent, Return on Equity (ROE) of 31 Percent and Return on Investment (ROI) of 21.7% with Gross margin of 32.9 percent and Operating & Profit margin of 10% and 7.8% respectively.